Stoke TherapeuticsNASDAQ: STOK

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences: Goldman Sachs 45th Annual Global Healthcare Conference Date: Monday, June 10, 2024 Time: 4:00 p.m. ET TD Cowen Genetic Medicines & RNA Summit Date: Thursday, June 20, 2024 Time: 1.

Stoke Therapeutics, Inc. (STOK) reported a quarterly loss of $0.57 per share, slightly better than the expected loss of $0.60 per share according to the Zacks Consensus Estimate. This is compared to a loss of $0.53 per share in the same quarter last year.

Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.65 per share a year ago.

Stoke Therapeutics (STOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Stoke Therapeutics, Inc. (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The mean of analysts' price targets for Stoke Therapeutics, Inc. (STOK) points to a 284.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Stoke Therapeutics, Inc. (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

The consensus price target hints at a 220.8% upside potential for Stoke Therapeutics, Inc. (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.